HAART Model 300 Annuloplasty Ring

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This investigation is a prospective, non-randomized, multi-center trial to evaluate the safety and effectiveness of the HAART model 300 annuloplasty ring when used to surgically repair a leaking aortic valve using a 3-D intra-annular mounting frame

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HAART 200 Aortic Valve Annuloplasty Trial

NCT02071849

Aortic Insufficiency

COMPLETED NA

HAART Annuloplasty Device Valve Repair Registry

NCT04035356

Aortic Valve Insufficiency Aortic Aneurysm

TERMINATED

Towards a More Standardized Bicuspid Aortic Valve Repair: Rationale and Design of CONTOUR Trial - a Randomized Trial

NCT06869954

Bicuspid Aortic Valve (BAV) Aortic Regurgitation Disease

RECRUITING NA

Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study

NCT00554151

Mitral Valve Regurgitation

COMPLETED NA

Preoperative CT-imaging with Patient-specific Computer Simulation in Transcatheter Aortic Valve Replacement

NCT05788770

Aortic Valve Stenosis

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aortic Regurgitation, (also known as Aortic Insufficiency; AI), is the failure of the aortic valve to close completely during diastole which causes blood to flow from the aorta back into the left ventricle. Aortic Regurgitation (AR) is a frequent cause of both disability and death due to congestive heart failure, primarily in individuals forty or older, but can also occur in younger populations.

Traditionally management of aortic regurgitation has been by aortic valve replacement, however, as has been observed in patients who have had mitral valve repair, the option of maintaining ones native aortic valve versus a replacement, either bioprosthetic or mechanical, can have added multiple benefits. The advantage of repair is the avoidance of prosthetic valve-related complications with bioprosthetic valves over 10-15 years or the need for anticoagulation with mechanical valves and the related problems of this therapy. Therefore, potentially aortic valve repair is a good option for patients with AR or AI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HAART 300 Annuloplasty Device

Implantation of HAART 300 Annuloplasty Device for aortic valve repair

Group Type EXPERIMENTAL

HAART 300 Annuloplasty Device

Intervention Type DEVICE

Implantation of device for aortic valve repair

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HAART 300 Annuloplasty Device

Implantation of device for aortic valve repair

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is 50 years old or older
* The subject has a tricuspid aortic valve morphology
* Patients with documented severe aortic insufficiency with aortic annular dilation without severe concomitant aortic stenosis
* Patients referred to center for documented moderate to severe Chronic aortic regurgitation (AR) associated with annular dilatation with or without cusp prolapse of one, two, or all three leaflets
* Patients with or without Sinotubular Junction (STJ) dilatation or aortic root aneurysms
* Patients who are free of coronary disease or those with evidence of minor stable (1-2 vessel) coronary disease
* Subject is willing to comply with specified follow-up evaluations, including transesophageal echocardiography if there are inadequate images by transthoracic echocardiography (TTE) to assess the aortic valve
* The subject has signed the written informed consent
* The subject agrees to return for all follow-up evaluations for the duration of the study (i.e. geographically stable
* The subject is New York Hospital Association (NYHA) class II or III

Exclusion Criteria

* The subject has preexisting valve prosthesis in the atrial, the mitral, pulmonary, and/or tricuspid position
* The subject requires an additional valve replacement
* The subject's aortic valve morphology is not tricuspid
* The subject has active endocarditis
* Heavily calcified valves
* Valvular retraction with severely reduced mobility
* The subject has mixed stenosis and regurgitation of the aortic valve with predominant stenosis
* The subject requires a repair of the mitral or tricuspid valve with the use of an annuloplasty device
* Leukopenia
* Acute anemia (Hb \< 9mg%)
* Platelet count \<100,000 cell/mm3
* Need for emergency surgery for any reason
* History of bleeding diathesis or coagulopathy or the subject refuses blood transfusions
* Active infection requiring antibiotic therapy (if temporary illness, subjects may enroll 4 weeks after discontinuation of antibiotics)
* Subjects in whom transesophageal echocardiography (TEE) is contraindicated
* Non elective presentation
* Low Ejection Fraction (EF) EF \< 40%
* Life expectancy \< 1 year
* Rheumatic disease
* The subject has severe leaflet fenestration or leaflets damaged by endocarditis
* The subject is or will be participating in a concomitant research study of an investigational product or has participated in such a study within the 30 days prior to screening
* The subject is a minor, an illicit drug user, alcohol abuser, prisoner, institutionalized, or is unable to give informed consent
* The subject is pregnant or lactating
* This patient will not agree to return to the implant center for the required number of follow-up visits or is geographically unavailable for follow-up
* The subject has not signed and dated the study informed consent
* Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA)
* Myocardial infarction (MI) within one month of trial inclusion
* Have a known intolerance to titanium or polyester
* Sole therapy for correction for patients with aortic root aneurysm
* Subjects requiring simultaneous cardiac procedures
* The subject has asymptomatic AR and a left ventricular ejection fraction (LVEF) \> 50%

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No